The Doxorubicin Market size (volume and value) and Market chain structure published by the insight partners through its high-quality database which is a valuable source of guidance and direction for companies and individual interested in the Market. Major companies with their market volumes and revenues are covered for each of the regions (north america, europe, asia pacific, middle east & africa, south & central america).

An exclusive Doxorubicin Market research report provides depth analysis of the market dynamics across five regions such as North America, Europe, South America, Asia-Pacific, Middle East and Africa.

According to our latest study, titled “Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – By Drug Formulation, Distribution Channel, and Geography," the market is expected to reach US$ 1,983.40 million in 2028 from US$ 1,390.64 million in 2022. It is estimated to grow at a CAGR of 6.1% during 2022–2028. The report highlights the key factors driving the doxorubicin market growth and prominent players with their developments in the global doxorubicin market. Key factors driving the market's growth are the increasing prevalence of cancer and the increasing preference for chemotherapy. However, the potential side effects associated with doxorubicin are expected to restrict the market growth during the forecast period.

The prominent/emerging players in the Doxorubicin Market research include:

Accord Healthcare
Cipla Inc.
Reddy's Laboratories
Meiji Holdings Co., Ltd.
Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Baxter International Inc.
Zydus Cadila
The market for doxorubicin before the pandemic was constantly growing as regular cancer screening, consultations, and treatments were going on. The market was highly affected due to the outbreak of Covid-19. The first wave of COVID-19 disrupted the consultations, follow-ups, screenings, and oncological cases' treatments. As a result, health care systems were overburdened, and the delivery of medical care to all patients became a challenge in the region. In addition, most pharmaceutical and medical device companies and research institutes were engaged in developing COVID-19 vaccines and related products. The chaotic situation was created in the healthcare industry across the countries, leading to a reduced number of consultations and a smaller number of cancer cases diagnosed. For instance, international efforts suggest that the diagnoses of cancers were reduced by 40% between March 9 and May 17, 2020, compared to diagnoses averaged over the same period in 2018 and 2019. In its disruption of clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the global doxorubicin market.

Based on drug formulation, the global doxorubicin market is segmented into lyophilized powder and doxorubicin injection. In 2022, the lyophilized powder will likely account for a larger market share. Moreover, the same segment is anticipated to register the highest CAGR in the market from 2022 to 2028. The major driving factor for the growth of the lyophilized powder segment is its storage stability, which maintains its solid state at room temperature. Lyophilized powder can be used as a chemotherapy drug against various cancer types, such as lymphoma, carcinoma, and various sarcomas. , Doxil is the first successful liposome-based product for treating patients with ovarian cancer and AIDs-related Kaposi’s sarcoma, which Johnson and Johnson manufactured.

The table of content for Market research study includes:

Introduction
Key takeaways
Research methodology
Market landscape
key market dynamics
Global market analysis
Revenue and forecasts to 2028 – type
Revenue and forecasts to 2028 – type of product
Revenue and forecasts to 2028 – service
Revenue and forecasts to 2028 – geographical analysis
Impact of covid-19 pandemic on global market
Industry landscape
key company profiles
Appendix
List of tables
List of figures
Company overview:

Company overview provides the information about location of the company where it is headquartered along with the established year, employee strength as of 2017, regions where the company is operating and the key business areas.

Product benchmarking:

Product benchmarking comprises the comprehensive list of products pertaining to the respective market along with the application and key features.

Strategic initiatives:

Insights pertaining to the new product launch, strategic collaboration, mergers and acquisition, regulatory approval, and other developments by the company in market are covered under strategic initiatives section.

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876